Total medical devices industry deals for September 2020 worth $11.62bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 43% over the previous month and a rise of 16.8% when compared with the last 12-month average of $9.95bn.
In terms of number of deals, the sector saw a drop of 12.3% over the last 12-month average with 135 deals against the average of 154 deals.
In value terms, North America led the activity with deals worth $10.18bn.
Medical devices industry deals in September 2020: Top deals
The top five medical devices deals accounted for 84.2% of the overall value during September 2020.
The combined value of the top five medical devices deals stood at $9.79bn, against the overall value of $11.62bn recorded for the month.
The top five medical devices industry deals of September 2020 tracked by GlobalData were:
1) Illumina’s $8bn acquisition of Grail
2) The $780m acquisition of Advanced Instruments by Patricia Industries
3) Corza Health’s $415.4m asset transaction with Takeda Pharmaceutical
4) The $350m private equity deal with North American Science Associates by ArchiMed
5) Smith & Nephew’s asset transaction with Integra LifeSciences for $240m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.